A glitch at Aspen Pharmacare Holdings Ltd.’s manufacturing plant has halted output of oral contraceptives, sparking a nationwide shortage. Health officials confirmed that pharmacies across South Africa are running low on the daily‑use pills, prompting concerns among women who rely on the medication for family planning. The disruption stems from a production line failure that officials say will take weeks to resolve before the next batch.

Retail chain Dis‑Chem, one of the country’s largest drugstores, reported empty shelves and redirected customers to alternative brands, albeit at higher prices. Analysts warn that reduced availability could pressure Aspen’s earnings, as the company commands a sizable share of the domestic contraceptive market. Investors may see the episode reflected in short‑term stock volatility as traders reassess supply‑risk exposure in the coming quarter.

The health ministry has urged the firm to expedite repairs and explore temporary imports to fill the gap, while NGOs call for contingency plans to protect women’s reproductive health. With contraceptive access tied to broader public‑health outcomes, the episode underscores how a single manufacturing hiccup can ripple through a market and affect consumer confidence for the upcoming season.